Rosnilimab for Rheumatoid Arthritis
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores the safety and effectiveness of a new treatment called Rosnilimab for individuals with moderate to severe Rheumatoid Arthritis (RA). Participants will receive varying doses of Rosnilimab or a placebo to evaluate the treatment's efficacy and tolerability. Ideal candidates have had RA for at least three months, are on a stable treatment plan with one or two RA medications, and have experienced inadequate results or issues with past treatments. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, providing participants an opportunity to contribute to the development of potentially effective RA therapies.
Will I have to stop taking my current medications?
No, you will not have to stop taking your current medications. Participants must continue taking at least one, but not more than two, csDMARDs (a type of medication for rheumatoid arthritis) at stable dosages throughout the trial.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that rosnilimab was well-tolerated in earlier studies. Few participants left the studies, and researchers found no major safety issues. Unlike some treatments for rheumatoid arthritis, such as JAK inhibitors, rosnilimab did not cause concerning side effects. This suggests that rosnilimab might be safe for those considering joining a clinical trial.12345
Why are researchers excited about this trial's treatment for RA?
Rosnilimab is unique because it targets a specific protein involved in the inflammatory process of rheumatoid arthritis, potentially offering a new mechanism of action compared to current treatments like methotrexate or biologics such as TNF inhibitors. Researchers are excited because Rosnilimab is administered subcutaneously, which might offer a more convenient and less invasive alternative to intravenous options. Additionally, Rosnilimab's ability to modulate the immune response differently could mean fewer side effects and improved outcomes for patients who don't respond well to existing therapies.
What evidence suggests that Rosnilimab could be an effective treatment for Rheumatoid Arthritis?
Research has shown that Rosnilimab, which participants in this trial may receive, may effectively treat rheumatoid arthritis (RA). In one study, patients experienced significant improvements, including symptom relief. Rosnilimab targets and reduces harmful T cells, which are part of the immune system and contribute to RA. Specifically, patients in that study demonstrated lasting improvements in their condition over time. Overall, Rosnilimab has proven effective and safe in these studies.12367
Are You a Good Fit for This Trial?
This trial is for adults with moderate to severe Rheumatoid Arthritis who have been diagnosed at least 3 months prior and are currently on stable doses of up to two conventional synthetic DMARDs. It's not open to pregnant or breastfeeding women, those with other joint diseases, previous PD-1/PD-L1 treatment, recent cancer history, or compromised immune systems.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Rosnilimab or placebo subcutaneously for 12 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- ANB030
Find a Clinic Near You
Who Is Running the Clinical Trial?
AnaptysBio, Inc.
Lead Sponsor